Royalty Pharma (RPRX) is back in focus after announcing a US$500 million R&D co funding agreement with Johnson & Johnson to advance JNJ-4804, an investigational autoimmune therapy targeting IL-23 and TNF pathways.
See our latest analysis for Royalty Pharma.
The J&J co funding news lands on top of an already strong run, with Royalty Pharma’s 90 day share price return of 18.98% and 1 year total shareholder return of 51.96% suggesting momentum has been building.
If this kind of deal making has your attention, it could be a good time to look at other healthcare names and review our screener for 34 healthcare AI stocks
With Royalty Pharma trading at US$47.90 against an average analyst price target of US$51.56 and an indicated intrinsic discount of 75.29%, is there still an investment opportunity here or is the market already pricing in future growth?
Most Popular Narrative: 7.1% Undervalued
Royalty Pharma’s most followed narrative pegs fair value at $51.56 versus the last close of $47.90, framing the recent move in the context of longer term cash flow potential and royalty deal activity.
The robust scientific pipeline, driven by advancements in biologics, gene therapies, and next-generation medicines like daraxonrasib, creates high-value assets that can enter into blockbuster status. Participation in these early, high-impact assets (as in the Revolution Medicines deal) positions Royalty Pharma for long-duration, high-growth royalty streams, directly benefitting long-term revenue and earnings.
Want to see what kind of revenue path and profit profile sit behind that valuation gap? The narrative leans heavily on sustained portfolio growth, slower margins, and a richer future earnings multiple that asks investors to back a very specific earnings and buyback script.
The narrative uses a 6.978% discount rate and ties the $51.56 fair value to detailed assumptions for revenue, earnings and share count, so it is worth comparing those inputs with your own expectations for Royalty Pharma’s royalty pipeline and deal execution before leaning on the target.
Result: Fair Value of $51.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story leans heavily on continued deal flow and smooth execution, while legal disputes and concentration in a few key royalties could quickly challenge those assumptions.
Find out about the key risks to this Royalty Pharma narrative.
Another View: Earnings Multiple Sends a Different Signal
The popular narrative leans on discounted cash flows and sees Royalty Pharma as 75.3% below fair value, yet the current P/E of 26.6x tells a different story. That is well above the US Pharmaceuticals industry at 16.5x, the peer average at 20.4x, and even the fair ratio of 20.1x suggested by regression analysis. In simple terms, the market is already paying a premium for each dollar of earnings, so is this really a discount or could expectations be running ahead of themselves?
For a closer look at what the numbers imply if the share price were to drift toward that fair ratio or back toward peer and industry levels, have a read of our valuation breakdown and See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mix of optimism and concern in this story feels finely balanced, now is the time to check the data yourself. Decide where you stand by weighing up the 2 key rewards and 2 important warning signs
Looking for more investment ideas?
If this story has sharpened your thinking, do not stop here. Use curated stock lists to spot fresh ideas before they are crowded and prices adjust.
- Target resilience by focusing on companies that pair staying power with measured risk using the 72 resilient stocks with low risk scores.
- Hunt for quality at a sensible price by scanning the 63 high quality undervalued stocks and see which names currently screen as potentially mispriced.
- Zero in on robust finances and durable business models through the solid balance sheet and fundamentals stocks screener (40 results) so you are not relying on hope alone.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com